SCHEMBL9898940

SCHEMBL9898940

CC(N)(CC(=O)O)c1cc([N+](=O)[O-])ccc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.47
HTT P42858 3/20 0.47
GAA P10253 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
THRB P10828 1/20 0.47
HIF1A Q16665 1/20 0.43
MAPT P10636 6/20 0.43
KMT2A Q03164 5/20 0.43
MEN1 O00255 4/20 0.40
LMNA P02545 3/20 0.40
POLB P06746 2/20 0.40
CYP1A2 P05177 1/20 0.40
PLG P00747 1/20 0.39
CYP3A4 P08684 1/20 0.39
ALOX15 P16050 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
GALR3 O60755 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KDM4E B2RXH2 2/20 0.38
MAPK1 P28482 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9898944 1.00 ALDH1A1 (0.47) ALDH1A1HTTGAAL3MBTL1THRB
SCHEMBL4077302 1.00 ALDH1A1 (0.47) ALDH1A1HTTGAAL3MBTL1THRB
SCHEMBL12350182 0.89 ALDH1A1 (0.47) ALDH1A1HTTGAAL3MBTL1THRB
SCHEMBL12350206 0.86 ALDH1A1 (0.43) ALDH1A1HTTGAAL3MBTL1THRB
SCHEMBL287615 0.86 ALDH1A1 (0.47) ALDH1A1HTTGAAL3MBTL1THRB
SCHEMBL12350209 0.86 ALDH1A1 (0.44) ALDH1A1HTTGAAL3MBTL1THRB
SCHEMBL287614 0.86 ALDH1A1 (0.47) ALDH1A1HTTGAAL3MBTL1THRB
SCHEMBL1440527 0.84 ALDH1A1 (0.48) ALDH1A1HTTGAAL3MBTL1THRB
SCHEMBL1440524 0.84 ALDH1A1 (0.48) ALDH1A1HTTGAAL3MBTL1THRB
SCHEMBL20894943 0.84 LMNA (0.47) ALDH1A1HTTGAAL3MBTL1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3194396-B1 DIAZINE-FUSED AMIDINE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME (US) 2019-04-17 EP disclosed
US-9868738-B2 Diazine-fused amidines as BACE inhibitors, compositions, and their use MERCK SHARP & DOHME CORP. (US) 2018-01-16 US disclosed
US-20170247377-A1 DIAZINE-FUSED AMIDINES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2017-08-31 US disclosed
EP-3194396-A1 DIAZINE-FUSED AMIDINE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE Merck Sharp & Dohme Corp. (US) 2017-07-26 EP disclosed
WO-2016044120-A1 DIAZINE-FUSED AMIDINE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2016-03-24 WO disclosed
EP-2485590-B1 PENTAFLUOROSULFUR IMINO HETEROCYCLIC COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME (US) 2015-01-07 EP disclosed
US-8557826-B2 Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use MERCK SHARP & DOHME CORP. (US) 2013-10-15 US disclosed
US-20120148603-A1 PENTAFLUOROSULFUR IMINO HETEROCYCLIC COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS, AND THEIR USE SCHERING CORPORATION (US) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170247377-A1 DIAZINE-FUSED AMIDINES AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE BACE1, BACE2, APP ALDH1A1 385/4885HTT 339/4885GAA 255/4885
US-20120148603-A1 PENTAFLUOROSULFUR IMINO HETEROCYCLIC COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS, AND THEIR USE BACE1, APP, BACE2 ALDH1A1 487/4885HTT 320/4885GAA 831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.